2024 Volume 15 Issue 1 Pages 48-53
[Objective] This study aimed to determine the difference in filter lifetime (FLT) between AN69ST and PMMA membranes during continuous kidney replacement therapy (CKRT) with nafamostat mesylate (NM). [Subjects and Methods] The study included 45 septic patients admitted to our facility between December 2018 and February 2023 and underwent CKRT using AN69ST or PMMA membrane in the initial circuit. NM dosage, circuit activated clotting time (ACT), FLT, and the incidence of circuit clotting within 24 h were compared between the two groups. [Results] The study included 26 and 19 patients in the AN69ST and PMMA groups, respectively. The NM dosage was 30 (20-30) and 14 (8-20) mg/h and the ACT was 176 (147-198) and 241 (204-326) sec in the AN69ST and PMMA groups, respectively (p ＜ 0.01 for both). However, FLT was 16.4 (6.5-43.5) and 27.7 (14.5-35.8) h in the AN69ST and PMMA groups, respectively, with no significant difference between the two groups (p=0.69). Further, the incidence of circuit clotting within 24 h was 16 (61.5%) and 10 circuits (52.6%) in the AN69ST and PMMA groups, respectively, with no significant difference between the two groups (p=0.55). [Conclusion] We did not find any significant differences in FLT between the AN69ST and PMMA groups.
